Perspective |
Featured
-
-
Perspective |
Artificial intelligence in liver cancer — new tools for research and patient management
Artificial intelligence (AI) is advancing rapidly and is already starting to transform cancer research and care. Here, the authors outline how AI could be incorporated into liver cancer management, highlighting areas with academic, commercial and clinical potential, as well as ongoing progress and pitfalls.
- Julien Calderaro
- , Laura Žigutytė
- & Jakob Nikolas Kather
-
Clinical Outlook |
New understanding of hepatobiliary MRI
Magnetic resonance imaging following injection of hepatobiliary contrast agents improves the detection of hepatocellular carcinomas when contrast agent accumulations in tumours and the surrounding pathological liver differ. However, tissue accumulation is poorly investigated, and this Clinical Outlook article highlights experimental data to understand better contrast agent accumulation in human pathological livers.
- Catherine M. Pastor
- & Valérie Vilgrain
-
-
Comment |
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa
Fatty liver disease is one of the most common liver diseases in the Middle East and North Africa region, and globally. Unfortunately, there is a lack of awareness regarding this condition. The nomenclature changes for NAFLD (to MAFLD or MASLD) have gained considerable attention in the hepatology community. Here, we present our point of view on this ongoing change and debate.
- Yasser Fouad
- , Salma Barakat
- & Hasmik Ghazinyan
-
Perspective |
Screening for liver fibrosis: lessons from colorectal and lung cancer screening
In this Perspective, Ginès and colleagues discuss liver fibrosis screening programmes using insights from colorectal and lung cancer screening.
- Maja Thiele
- , Patrick S. Kamath
- & Pere Ginès
-
-
In Brief |
Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence
- Jordan Hindson
-
Review Article |
Hepatic glucose metabolism in the steatotic liver
Hepatic metabolic functions are altered in metabolic diseases. This Review provides a comprehensive overview of glucose metabolism in steatotic liver disease (SLD) and obesity, describes new techniques for hepatic glucose flux assessment and discusses how SLD treatments affect glucose metabolism.
- Egeria Scoditti
- , Silvia Sabatini
- & Amalia Gastaldelli
-
Year in Review |
Novel interventions against alcohol-related liver disease
In 2023, there were significant advancements in trials of interventions to reduce mortality and morbidity from alcohol-related liver disease, spanning the entire spectrum of disease: primary prevention to reduce overall alcohol-related harm, secondary prevention to attenuate fibrosis progression and tertiary prevention using antibiotics for severe alcohol-associated hepatitis.
- Maja Thiele
- & Christophe Moreno
-
Comment |
Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases
Steatotic liver disease has emerged as an important risk factor for cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease. Successful treatment of steatotic liver disease might also be effective in preventing these cardiometabolic diseases.
- Norbert Stefan
- , Amedeo Lonardo
- & Giovanni Targher
-
-
News & Views |
Implications of the evolving knowledge of the genetic architecture of MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) has a strong heritable component, and genome-wide association cohort studies are highlighting the major genetic determinants of this condition. A meta-analysis of these databases has now enabled expansion of the list of the inherited variants that modulate the risk of MASLD. The identification of new MASLD risk loci is improving comprehension of disease pathogenesis and individual risk stratification, and also enabling the identification of novel therapeutic targets and disease subtypes that might ultimately lead to a precision medicine approach.
- Luca V. C. Valenti
- & Vittoria Moretti
-
-
-
-
-
Perspective |
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
Cirrhosis recompensation is gradually gaining traction, but a definition for recompensation in nonalcoholic fatty liver disease (NAFLD)-related cirrhosis is currently lacking. This Perspective provides an overview of the natural history of NAFLD and discusses NAFLD-related cirrhosis recompensation.
- Gong Feng
- , Luca Valenti
- & Ming-Hua Zheng
-
Perspective |
Digital pathology for nonalcoholic steatohepatitis assessment
Histological assessment of nonalcoholic fatty liver disease (NAFLD) is essential for clinical practice as it outlines diagnosis and lays the foundation of medical care. This Perspective summarizes the advancements in digital histology and discusses current and future applications in NAFLD.
- Arun J. Sanyal
- , Prakash Jha
- & David E. Kleiner
-
-
-
-
-
Editorial |
Turning our focus to liver fibrosis
Liver fibrosis is a substantial risk factor for liver cancer development. In this issue, we focus on molecular and cellular mechanisms of hepatic fibrogenesis and discuss therapeutic implications.
-
Review Article |
Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis
Increasing evidence shows a role of cellular stress responses in nonalcoholic steatohepatitis (NASH) and liver fibrosis pathogenesis. This Review provides a comprehensive overview of the molecular mechanisms involved in cellular stress in fibrogenesis and their role in NASH progression.
- Sachin Sharma
- , Dounia Le Guillou
- & Jennifer Y. Chen
-
-
Review Article |
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
In this Review, Arrese and colleagues discuss the intersection of nonalcoholic fatty liver disease and alcohol-related liver disease, including their pathophysiology, clinical management and suggestions for future research.
- Luis Antonio Díaz
- , Juan Pablo Arab
- & Marco Arrese
-
-
Review Article |
Friend or foe? The elusive role of hepatic stellate cells in liver cancer
Hepatic stellate cells (HSCs) drive liver fibrosis and are closely linked to liver cancer development. This comprehensive Review provides an in-depth analysis of the specific characteristics of HSCs in cancer, highlighting therapeutic implications based on progress in clarifying HSC biology.
- Bruno Cogliati
- , Chittampalli N. Yashaswini
- & Scott L. Friedman
-
Clinical Outlook |
The current status of imaging in liver fibrosis
Imaging techniques for assessing liver fibrosis are advancing. This Clinical Outlook article discusses the best practices and reviews emerging options for magnetic resonance and ultrasound-based elastography.
- Kathryn J. Fowler
- & Mustafa R. Bashir
-
-
-
-
Review Article |
Lifestyle interventions in nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NALFD) prevalence, including in children and adolescents, is rising worldwide. This Review offers a comprehensive overview of the lifestyle interventions available for NAFLD, including dietary and physical-activity strategies.
- Zobair M. Younossi
- , Shira Zelber-Sagi
- & Lynn H. Gerber
-
Review Article |
Hepatic inflammatory responses in liver fibrosis
Liver inflammation is a key process that orchestrates intrahepatic injury. This Review offers a comprehensive overview of the inflammatory mechanisms of hepatic fibrosis and discusses current advances and therapeutic implications.
- Linda Hammerich
- & Frank Tacke
-
-
-
-
Comment |
Measuring NAFLD models of care
In this Comment, we provide a strategic framework for what could and should be measured, across four domains, to optimize standards of care for multidisciplinary models of care in nonalcoholic fatty liver disease.
- Alina M. Allen
- , Zobair M. Younossi
- & Jeffrey V. Lazarus
-
Perspective |
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Tackling fibrosis in patients with nonalcoholic steatohepatitis (NASH), one of the major causes of liver cirrhosis, is critical in improving patient outcomes. This Perspective discusses potential strategies to develop better antifibrotic therapies in NASH, from the discovery process to future clinical trials.
- Paul N. Brennan
- , Ahmed M. Elsharkawy
- & Jonathan A. Fallowfield
-
-
Research Highlight |
Elucidating the link between clonal haematopoiesis and chronic liver disease
- Jordan Hindson
-
-
News & Views |
Liver fibrosis with methotrexate — an overestimated risk?
A prospective study suggests that the risk of liver fibrosis with methotrexate treatment has been overestimated. The findings suggest the need to reconsider the intensive strategies and the screening tools that are recommended for monitoring liver fibrosis in patients receiving methotrexate.
- Raul J. Andrade
- & Einar S. Björnsson
-
-
-
Review Article |
Global epidemiology of cirrhosis — aetiology, trends and predictions
In this Review, Huang et al. highlight global trends in the epidemiology of cirrhosis, including contributions of various aetiologies of liver disease, and consider what needs to be done to address projected increases in the burden of cirrhosis.
- Daniel Q. Huang
- , Norah A. Terrault
- & Rohit Loomba
-
Review Article |
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
In this Review, Llovet and colleagues discuss advances in our knowledge of the pathogenesis and clinical management of nonalcoholic steatohepatitis-related hepatocellular carcinoma. They also discuss future prospects and unmet needs.
- Josep M. Llovet
- , Catherine E. Willoughby
- & Scott L. Friedman
-
-
Research Highlight |
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis
- Ian Fyfe
Spatial genomics: mapping human steatotic liver disease
Role of intestinal B cells in NASH and liver fibrosis
Nanoparticles in NAFLD therapeutics